Conceivable Life Sciences, a biotech company revolutionizing the future of fertility care with the end-to-end automation of the IVF lab, announced the closing of an $18 million Series A financing. ARTIS Ventures led the round with participation from new investors, including Atlantic Health Venture Studio, Muse Capital, and Scrub Capital. Existing investors include ACME Capital, Black Opal Ventures, Cadence Healthcare Ventures, Future Positive Capital, Stride.VC, and Time BioVentures. Conceivable has raised over $39 million so far.
Conceivable synthesizes AI and robotics for automating the 200+ intricate steps required to create embryos for IVF, routinely performing delicate single-cell surgery at the microscopic level. And the company achieved the world’s first fully automated intracytoplasmic sperm injection (ICSI), performed both onsite and remotely, spanning 3,000 miles between the reproductive cells within Conceivable’s system and the embryologist operator in New York. This achievement was the subject of a mainstage presentation at the 2024 European Society of Human Reproduction and Embryology (ESHRE).
The Series A funding will support a commercial pilot, which includes a 100-patient Institutional Review Board (IRB) study currently underway. In a prior IRB study using its first-generation AI and automation platform, 22 pregnancies were achieved upon the first embryo transfer. Along with advancing its pilot, Conceivable will use the funding to prepare for a U.S. launch targeted for early 2026.
KEY QUOTES:
“Despite significant clinical advances since the first IVF child was born almost 50 years ago, IVF labs remain largely manual, artisanal, and lacking in the kind of automation and robotics that have transformed other branches of advanced medicine. Our world-class, interdisciplinary team of experts in embryology, automation, AI, robotics, advanced optics, and machine vision is transforming this outdated model. Even in early testing, our clinical outcomes rival the best IVF labs in the world. As we accelerate our program to expand access, we anticipate even better results, heralding a new chapter in IVF.”
- Dr. Alejandro Chavez-Badiola, reproductive endocrinologist, co-founder, and Chief Product Officer of Conceivable
“I am incredibly proud of the scientific foundation, exceptional team, and encouraging data that we have achieved at Conceivable. This funding allows us to build on our momentum with the support of leading investors who bring deep expertise in reproductive medicine.”
- Alan Murray, co-founder and Chief Executive Officer of Conceivable
“We are honored to welcome ARTIS, Atlantic Health Venture Studio, Muse Capital, and Scrub Capital to our distinguished investor base. Their confidence underscores the transformative potential of our technology to meet the immense and unmet demand for IVF globally.”
- Joshua Abram, co-founder and Chairman of Conceivable
“Conceivable’s approach to IVF, combining AI and cutting-edge robotics to create an entirely new 21st-century model for IVF, will transform the field worldwide, catalyzing a new era of quality, scale, accessibility, and follow-on innovation. Even in the U.S., 80% of infertile couples go untreated, unable to access IVF because of high cost, proximity to care, or both. Conceivable is creating a scalable solution that democratizes IVF and delivers equity in fertility care.”
- Stuart Peterson, founder and Managing Partner at ARTIS Ventures
“Starting a family is a deeply personal and yet universal experience. Our mission at Conceivable is to make IVF affordable to everyone who needs it. Given the high costs of IVF treatment today, this is not the reality. Conceivable’s innovation will radically increase accessibility to IVF and achieve better clinical outcomes for patients.”
- Aike Ho, a Partner at ACME Capital who, with her wife, has undergone IVF using Conceivable technology
